Foghorn Therapeutics Inc 's Revenue in the fiscal year 2025 $ 30.91 millions
Foghorn Therapeutics Inc 's Revenue in the fiscal year 2024 $ 22.60 millions
Foghorn Therapeutics Inc 's Revenue in the fiscal year 2023 $ 34.16 millions
Foghorn Therapeutics Inc 's Revenue in the fiscal year 2022 $ 19.23 millions
Foghorn Therapeutics Inc 's Revenue in the fiscal year 2021 $ 1.32 millions
FHTX Revenue third quarter 2026 Y/Y Growth Comment
Foghorn Therapeutics Inc reported Revenue surge of 925.07% year on year in the third quarter 2026, to $ 83.54 millions, this is lower than Foghorn Therapeutics Inc 's recent average Revenue surge of 997.57%.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue growth. While Foghorn Therapeutics Inc ' s Revenue doubling of 925.07% ranks overall at the positon no. 232 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Foghorn Therapeutics Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
1639.02 %
118.08 %
-85.3 %
(Dec 31 2021)
FHTX's III. Quarter Q/Q Revenue Comment
Foghorn Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 419.87%, to $ 83.54 millions, from $16.07 millions in the second quarter. FHTX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Foghorn Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 57.
Foghorn Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 419.87%, to $ 83.54 millions, from $16.07 millions in the second quarter. FHTX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Foghorn Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 57.
Foghorn Therapeutics Inc 's 12 Months Revenue Growth Year on Year
Although Foghorn Therapeutics Inc 's Annual Revenue growth year on year were below company's average 288.56% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 51.98% year on year, from 20.08% in Mar 31 2026.
In the Healthcare sector 471 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3148 to 3462.
Although Foghorn Therapeutics Inc 's Annual Revenue growth year on year were below company's average 288.56% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 51.98% year on year, from 20.08% in Mar 31 2026.
In the Healthcare sector 471 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3148 to 3462.
About Foghorn Therapeutics Inc Revenue Growth Rates (FHTX), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1,438.05%